When was EyePoint Pharmaceuticals founded?

EyePoint Pharmaceuticals was founded in 1987 and raised its 1st funding round 31 years after it was founded.

Where is EyePoint Pharmaceuticals located?

EyePoint Pharmaceuticals is headquartered in Watertown, United States.

How many employees does EyePoint Pharmaceuticals have?

As of Mar 31, 2026, the latest employee count at EyePoint Pharmaceuticals is 251.

Is EyePoint Pharmaceuticals a funded company?

EyePoint Pharmaceuticals is a funded company, having raised an undisclosed amount across 5 funding rounds to date. The company's 1st funding round was a $***** Conventional Debt round, raised on Mar 28, 2018.

When was the latest funding round of EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals' latest funding was a $***** Post IPO round on Jan 03, 2021, with participation from 1 investor.

What is the annual revenue of EyePoint Pharmaceuticals?

Annual revenue of EyePoint Pharmaceuticals is between $10M and $50M as on Dec 31, 2024

Where does EyePoint Pharmaceuticals rank among its competitors?

EyePoint Pharmaceuticals ranks 18th amongst 111 active competitors, of which 43 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Kala Pharmaceuticals, which secured $1.75M in Mar, 2026.

Who are the top competitors of EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals' top competitors include 4D Molecular Therapeutics, Regenxbio and CureVac. Among them, Kala Pharmaceuticals secured the most recent funding round in March, 2026.

EyePoint Pharmaceuticals - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Developer of small molecule-based therapeutics for treating ophthalmic disorders. The company has developed its proprietary technology Durasert which is a miniaturized, injectable, sustained-release drug delivery system for small molecules. The company's lead product candidates are Yutiq for chronic non-infectious uveitis, and EYEP-1901 for wet AMD, diabetic retinopathy, and retinal vein occlusion.

Website: eyepointpharma.com
Social
Email ID: *****@eyepointpharma.com
Phone Number: +1 **********

Key Metrics

Founded Year

1987

Location

Watertown, United States

Stage

Public

Latest Funding Round

Post IPO, Jan 03, 2021, $*****

Investors

SWK Holdings & 4 more

Ranked

18^th among 111 active competitors

Annual Revenue

$10M - $50M as on Dec 31, 2024

Employee Count

251 as on Mar 31, 2026

Investment & Acquisitions

Icon Bioscience & 1 more

Similar Companies

4D Molecular Therapeutics & 115 more

Exit Details

Public

View EyePoint Pharmaceuticals' full profile

EyePoint Pharmaceuticals is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Psivida Corp. CIN: 1314102 , United States, Active		$10M - $50M (As on Dec 31, 2024)	49 (As on Dec 31, 2018)	-

EyePoint Pharmaceuticals got listed on Jan 27, 2005.

Click here to take a look at EyePoint Pharmaceuticals's IPO in detail

EyePoint Pharmaceuticals has raised funding over 5 rounds. Its first funding round was on Mar 28, 2018. Its latest funding round was a Post IPO round on Jan 03, 2021 for $*****. 1 investor participated in its latest round. EyePoint Pharmaceuticals has 5 institutional investors.

Here is the list of recent funding rounds of EyePoint Pharmaceuticals:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 03, 2021	6041570	Post IPO	8718488	2180530	9302256	3997050
Feb 13, 2019	6037812	Conventional Debt	7376193	9541838	8649246	CRG
Oct 02, 2018	7948522	Post IPO	4111619	1017026	7710396	EW Healthcare Partners & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of EyePoint Pharmaceuticals's funding rounds and investors

EyePoint Pharmaceuticals' employee count trend

EyePoint Pharmaceuticals has 251 employees as of Mar 26. Here is EyePoint Pharmaceuticals's employee count trend over the years:

Employee count trend for EyePoint Pharmaceuticals

Uncover EyePoint Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of EyePoint Pharmaceuticals include 4D Molecular Therapeutics, Regenxbio and CureVac. Here is the list of Top 10 competitors of EyePoint Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	4D Molecular Therapeutics 2013, Emeryville (United States), Public	Developer of gene therapeutics for genetic disorders	$187M	Viking Global Investors, CureDuchenne & 18 others	67/100
2nd	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Venrock, Brookside Capital & 15 others	67/100
3rd	CureVac 2000, Tubingen (Germany), Acquired	Developer of mRNA-based therapeutics against cancer and infectious diseases	$975M	Gates, Dievini & 16 others	67/100
4th	Kala Pharmaceuticals 2009, Waltham (United States), Public	Developer of ophthalmic treatments based on its mucosal penetrating product platform	$115M	Third Rock Ventures, Polaris Partners & 17 others	66/100
5th	Rezolute 2012, Denver (United States), Public	Developing transformative therapies for rare diseases, focusing on hyperinsulinism (HI)	-	Handok, Lincoln Park Capital & 8 others	64/100
6th	Aviceda Therapeutics 2018, Cambridge (United States), Series C	Developer of biotherapeutics for glycol-immune diseases	$255M	Omega Funds, Blue Owl & 10 others	63/100
7th	AAVantgarde Bio 2021, Milano (Italy), Series B	Developer of gene therapies using Adeno-Associated Viral vectors	$206M	Forbion, Atlas Venture & 11 others	63/100
8th	Outlook Therapeutics 2011, Cranbury (United States), Public	Developer of antibodies for ophthalmic disorders	$51.8M	Perceptive Advisors, GMS Holdings & 12 others	61/100
9th	Complement Therapeutics 2020, London (United Kingdom), Series A	Developer of gene therapies to treat retinal diseases	$84.8M	Forbion, Gimv & 7 others	61/100
10th	Opus Genetics 2021, Durham (United States), Public	Developer of gene therapies to treat retinal degenerative diseases	$23.5M	RD Fund, HHS & 2 others	59/100
18th	EyePoint Pharmaceuticals 1987, Watertown (United States), Public	Developer of small molecule-based therapeutics for treating ophthalmic disorders	-	SWK Holdings, EW Healthcare Partners & 3 others	57/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on EyePoint Pharmaceuticals's competitors? Click here to see the top ones

EyePoint Pharmaceuticals has acquired 2 companies including Icon Bioscience and Contractordeliverysystems. EyePoint Pharmaceuticals has not made any investments as of now.

Here is the latest report on EyePoint Pharmaceuticals's sector:

Free

Ophthalmology - Sector Report

Edition: May, 2026 (67 Pages)

View all reports related to EyePoint Pharmaceuticals

Media has covered EyePoint Pharmaceuticals for a total of 18 events in the last 1 year, 9 of them have been about company updates and 3 about people movement.